Agios Pharmaceuticals (Agios Pharmaceuticals) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Agios Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2024 was $-0.14 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-92.07 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Agios Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Agios Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Capex-to-Operating-Income Chart

Agios Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Agios Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Agios Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Agios Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Capex-to-Operating-Income falls into.

Agios Pharmaceuticals Capex-to-Operating-Income Calculation

Agios Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-18.499)	/	-391.487
	=	N/A

Agios Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.141)	/	-92.072
	=	N/A

Agios Pharmaceuticals (NAS:AGIO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Agios Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals (Agios Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

AGIO:Mexico 8AP:Germany 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Executives

Brian Goff	director, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens	officer: Chief Medical Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns	officer: Chief Legal Officer	C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Washburn Theodore James Jr.	officer: Principal Accounting Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen	director	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
David P Schenkein	director, 10 percent owner, officer: Chief Executive Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rahul D. Ballal	director	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Richa Poddar	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson	officer: Principal Accounting Officer	88 SIDNEY STREET, CAMBRIDGE MA 02139